Pharmaceutical company BioPharmX Corporation (NYSE American:BPMX) revealed on Wednesday the appointment of David S. Tierney, M.D., as its chief executive officer as well as a director of its board of directors.
Anja Krammer continues to serve as president and corporate secretary for the company.
Most recently, Dr Tierney has served as president and CEO of Icon Bioscience, where he led a team that in 2018 received US FDA approval of its New Drug Application (NDA) for DEXYCU (dexamethasone intraocular suspension), a dropless, long-acting therapeutic for treating inflammation associated with cataract surgery.
Previously, Dr Tierney was employed as president and chief operating officer of Oceana Therapeutics, Inc, president & CEO of Hydro Med Sciences (HMS), which emerged as Valera Pharmaceuticals, a fully integrated, commercial, specialty pharma company, as well as president of Biovail Technologies, a drug division of Biovail Corporation.
At the start of his career, Dr Tierney was a senior vice president of drug development at Roberts Pharmaceutical as well as part of Elan Corporation.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007